Feride DURMAZ YAMAN, Ayşin ŞAKAR ÇOŞKUN, Öznur KILIÇ SOYLAR, Oğuz KILINÇ, Aykut ÇİLLİ, Burcu ÇELENK KARABOĞA, Canan GÜNDÜZ, Mehmet Sezai TAŞBAKAN, Abdullah SAYINER

Serum procalcitonin and C-reactive protein kinetics as indicators of treatmentoutcome in hospitalized patients with community-acquired pneumonia

Background/aim: There has been growing interest in the use of serum procalcitonin (PCT) and C-reactive protein (CRP) in patients with community-acquired pneumonia (CAP). The aim of this study was to investigate whether an assessment of fever, leukocyte count, and serum CRP and PCT levels on admission and during follow-up (day 3) provides any information about the clinical outcome in hospitalized patients with CAP. Materials and methods: Patients with a diagnosis of CAP who were admitted to and followed at four university hospitals were evaluated retrospectively using the Turkish Thoracic Society Pneumonia Database. Results: A total of 103 hospitalized CAP patients (57 males, mean age: 61.5 ± 16.7 years) were enrolled in the study. Treatment failure (TF) was observed in 20 patients (19.4%). Pneumonia Severity Index scores, serum CRP levels, and PCT levels on admission were significantly higher in the TF group. There were significant decreases in CRP and PCT levels between admission day and day 3 in the treatment success group. Conclusion: In patients with CAP, the body temperature and leukocyte count on admission do not predict outcome. Monitoring levels of CRP and PCT may be useful as a predictor of treatment outcome.

PDF

___

1. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G. New perspectives on community-acquired pneumonia in 388,406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
2. Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, Benítez Moya JM, Ruiz-Manzano J, Rodríguez de Castro F, Blanquer J et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965.
3. Schuetz P, Koller M, Christ-Crain M, Steyerberg E, Stolz D, Müller C, Bucher HC, Bingisser R, Tamm M, Müller B. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect 2008; 136: 1628-1637.
4. Christ-Crain M, Opal SM. Clinical review: The role of biomarkers in the diagnosis and management of communityacquired pneumonia. Crit Care 2010; 14: 203.
5. Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T; CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349-355.
6. Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA, Martínez A, Esquinas C, Ramirez P, Torres A. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-591.
7. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011; 17: E1-E59.
8. Coelho L, Póvoa P, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92.
9. Torres A, Ramirez P, Montull B, Menéndez R. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012; 33: 266-271.
10. Lacoma A, Rodríguez N, Prat C, Ruiz-Manzano J, Andreo F, Ramírez A, Bas A, Pérez M, Ausina V, Domínguez J. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2012; 31: 825-833.
11. Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63: 447-452.
12. Ramírez P, Ferrer M, Martí V, Reyes S, Martínez R, Menéndez R, Ewig S, Torres A. Inflammatory biomarkers and prediction for intensive care unit admission in severe communityacquired pneumonia. Crit Care Med 2011; 39: 2211-2217.
13. Menéndez R, Martinez R, Reyes S, Mensa J, Polverino E, Filella X, Esquinas C, Martinez A, Ramirez P, Torres A. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987-992.
14. Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe communityacquired pneumonia. Intensive Care Med 2006; 32: 469-472.
15. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32: 726-732.
16. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. For the Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group 1. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011; 37: 384-392.